SA
Go ProLog In
BCRX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
28 analysts·High coverage
72
Score
25 Buy (89%)3 Hold (11%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2589%
Hold
311%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$8.00
-11.3%
Consensus
$15.00
+66.3%
Bull
$25.00
+177.2%
12-Month Target Range28 analysts
$8.00$15.00$25.00
Current $9.02Consensus
Current Price
$9.02
Upside to Consensus
$5.98

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+8.37%
EPS—
FY2028
Rev+18.80%
EPS+36.70%
FY2029
Rev+22.01%
EPS+113.23%

Earnings Surprises

Recent Analyst Actions

Nov 5, 2025JMP Securities
BioCryst price target lowered to $25 from $27 at Citizens JMP
Target:$25.00
+258.7%from $6.97
Nov 4, 2025Barclays
BioCryst price target lowered to $9 from $11 at Barclays
Target:$9.00
+31.2%from $6.86
Oct 14, 2025RBC Capital
BioCryst weakness presents 'compelling' buying opportunity, says RBC
Target:$15.00
+133.6%from $6.42
Oct 14, 2025Jefferies
BioCryst price target raised to $15 from $14 at Jefferies
Target:$15.00
+133.6%from $6.42
Oct 1, 2025Evercore ISI
BioCryst downgraded to In Line from Outperform at Evercore ISI
Target:$8.00
+10.5%from $7.24
Aug 6, 2024Barclays
BioCryst price target raised to $7 from $6 at Barclays
Target:$7.00
-6.8%from $7.51
Aug 5, 2024Jefferies
BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
Target:$11.00
+46.5%from $7.51
Nov 2, 2022Evercore ISI
UPDATE: Evercore ISI Upgrades BioCryst Pharma (BCRX) to Outperform
Target:$16.00
+29.2%from $12.38
Aug 23, 2022Barclays
BioCryst (BCRX) Stock: $14 Target And Equal-Weight Rating
Target:$14.00
-2.3%from $14.32
Jan 10, 2022Cowen & Co.
BioCryst Pharma (BCRX) PT Raised to $25 at Cowen on Orladeyo Sales Data
Target:$25.00
+69.1%from $14.78
Nov 3, 2021Cantor Fitzgerald
Analysts Offer Insights on Healthcare Companies: BioCryst (NASDAQ: BCRX) and Penumbra (NYSE: PEN)
Target:$21.00
+69.4%from $12.40
Aug 9, 2021Jefferies
Jefferies Downgrades BioCryst Pharma (BCRX) to Hold
Target:$19.00
+7.6%from $17.65

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance